No Detail Found!

High frequency of CYP2C19*3 heterozygotes among patients under clopidogrel treatment in Ouagadougou, Burkina Faso

Author(s)
Abdoul Karim Ouattara Université Norbert Zongo/Centre Universitaire de Manga, BP 376 Koudougou, Burkina Faso;“Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina Faso
Yves Donald Kagambega Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina Faso
Teega-Wendé Clarisse Ouédraogo Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina Faso ;Centre de Recherche Biomoléculaire Pietro Annigoni, 01 BP 364 Ouagadougou 01, Burkina Faso
Lassina Traoré Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO,03 BP 7021 Ouagadougou 03,Burkina Faso
Modeste Ouedraogo Service de Cardiologie du Centre Hospitalier Universitaire Yalgado Ouédraogo, 03 BP 7022 Ouagadougou 03, Burkina Faso
Nobila Valentin Yaméogo Centre de Recherche Biomoléculaire Pietro Annigoni, 01 BP 364 Ouagadougou 01, Burkina Faso
Jacques Simporé Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina Faso;Centre de Recherche Biomoléculaire Pietro Annigoni, 01 BP 364 Ouagadougou 01, Burkina Faso
Abstract
Backgrouanndd Objective: Despite its widespread use in cardiology, patient s responsteo clopidogrel exhibits significant interindividual variability, oftenleading to persistent thromboembolic complications. The hepatic Cytochrome P450 2C19 (CYP2C19) superfamily plays a pivotal role in clopidogrel's conversion to its active form and CYP2C19 polymorphisms significantly contribute to this variability. This study aimed to evaluate the prevalence and impact of the CYP2C19 rs4986893 polymorphism on clopidogrel treatment response. Materials and Methods: Seventy-three patients with Cardiovascular Diseases (CVD) undergoing clopidogrel antiplatelet therapy for a minimum of sixmonths wererecruited from Centre Hospitalier Unive rYaslgiadotOauéidrraoego (CHU-YO). Sociodemographic data were collected and DNA was extracted from blood samples for CYP2C19 rs4986893 genotyping using PCR-RFLP. Results: The patient's mean age was 62.56113.45 years, ranging from 23 to 94 years, with a male-to-female sex ratio of 1.28. Most patients came from the informal sector, primarily of Mossi ethnicity and residing in Ouagadougou. Acute coronary syndromes (ACS) and hypertension were the predominant reasons for consultation, with clopidogrel showing efficacy in 97.3% of cases. While 72.6% had no family history of CVD, hypertension was prevalent among those with familial cardiovascular conditions. Genetic analysis revealed a 65.8% frequency of heterozygotes CYP2C19%1/*3, with no mutant homozygotes CYP2C19*3/#3 detected. Theresults of the present study underscore a high prevalence of heterozygotes CYP2C19%1/*3 among patients with cardiovascular diseases. Conclusion: This intermediate metabolic phenotype, along with a good response to clopidogrel, suggests that CYP2C19%1/*3 genotype promotes a favourable response to clopidogrel therapy.
Publication Details
Page(s) 398-403
Published Journal: Pakistan Journal of Biological Sciences, Volume: 27, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
PCR-RFLP, cardiovascular diseases, Polymorphism, clopidogrel, CYP2C19, Burkina Faso
References
Gao B,Xu Y.,Leng J.,Wang K.,Xia B.,Huang J. .2015 .. , : .
Int. Heart J . .. , 56 : 341-344.
Bhatt D.L .2022 .Diagnosis and treatment of acute coronary syndromes: A review. Lopes and RA. Harrington, : .
JAMA . .. , 327 : 662-675.
Charfi R,Boughalleb M.,Hosni H.,Kouidhi S. .2018 .Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphismtunisienne. La Tunis. Medicale, 96 : 229-238.
Zeb N.,Krim J.,Bella J. .2018 .Role of CYP2C19 genotype testing In clinical use of clopidogrel: Is it really useful? Exp. , 16 : 369-377.
Lee CR,Sangkuhl K. .2022 .Clinical pharmacogenetics implementation consortium guideline for CYP2C719 genotype and clopidogrel therapy: 2022 update. Clin., : .
Pharmacol. Ther. . .. , 112 : 959-967.
Scott SA,K Sangkuhl SA .2013 .Clinical pharmacogenetics implementation consortium guidelines for CYP2C719 genotype and clopidogrel therapy: 2013 update. , : .
Pharmacol Clin. . .. , 94 : 317-323.
Miller S.A,D.D. Dykesand H.F.Polesky S.A .1988 .Asimple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16 : 1215-1215.
Ouattara BV.JT.E.,Bazie B.,Diarra B.,Compaore B. .2014 .-phosphate dehydrogenase (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso. , : .
Pac. J. Trop Asian,Adejumo O.,Ung D.,Xu Z,A Z,Mensah G.A.,Johnson C.O.,Ammirati E. .1990 .Update from the GBD 2019 study. J. Am. Coll. Cardiol, 76 : 2982-3021.
0

Citations

0

Downloads

27

Views